278 related articles for article (PubMed ID: 23068961)
1. C-peptide response to glucagon challenge is correlated with improvement of early insulin secretion by liraglutide treatment.
Takabe M; Matsuda T; Hirota Y; Hashimoto N; Nakamura T; Sakaguchi K; Ogawa W; Seino S
Diabetes Res Clin Pract; 2012 Dec; 98(3):e32-5. PubMed ID: 23068961
[TBL] [Abstract][Full Text] [Related]
2. Long-term liraglutide treatment is associated with increased insulin content and secretion in β-cells, and a loss of α-cells in ZDF rats.
Schwasinger-Schmidt T; Robbins DC; Williams SJ; Novikova L; Stehno-Bittel L
Pharmacol Res; 2013 Oct; 76():58-66. PubMed ID: 23891763
[TBL] [Abstract][Full Text] [Related]
3. Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions.
Mari A; Degn K; Brock B; Rungby J; Ferrannini E; Schmitz O
Diabetes Care; 2007 Aug; 30(8):2032-3. PubMed ID: 17468345
[No Abstract] [Full Text] [Related]
4. Liraglutide in the management of type 2 diabetes.
Wajcberg E; Amarah A
Drug Des Devel Ther; 2010 Oct; 4():279-90. PubMed ID: 21116334
[TBL] [Abstract][Full Text] [Related]
5. Restoring Insulin Secretion (RISE): design of studies of β-cell preservation in prediabetes and early type 2 diabetes across the life span.
RISE Consortium
Diabetes Care; 2014; 37(3):780-8. PubMed ID: 24194506
[TBL] [Abstract][Full Text] [Related]
6. The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes.
Moon HS; Kim MK; Son MH
Arch Pharm Res; 2011 Jul; 34(7):1041-3. PubMed ID: 21811909
[TBL] [Abstract][Full Text] [Related]
7. Predictive factors of efficacy of combination therapy with basal insulin and liraglutide in type 2 diabetes when switched from longstanding basal-bolus insulin: Association between the responses of β- and α-cells to GLP-1 stimulation and the glycaemic control at 6 months after switching therapy.
Horie I; Haraguchi A; Sako A; Akeshima J; Niri T; Shigeno R; Ito A; Nozaki A; Natsuda S; Akazawa S; Mori Y; Ando T; Kawakami A; Abiru N
Diabetes Res Clin Pract; 2018 Oct; 144():161-170. PubMed ID: 30194951
[TBL] [Abstract][Full Text] [Related]
8. Incretin effects on β-cell function, replication, and mass: the human perspective.
Garber AJ
Diabetes Care; 2011 May; 34 Suppl 2(Suppl 2):S258-63. PubMed ID: 21525465
[No Abstract] [Full Text] [Related]
9. Liraglutide and the preservation of pancreatic β-cell function in early type 2 diabetes: the LIBRA trial.
Retnakaran R; Kramer CK; Choi H; Swaminathan B; Zinman B
Diabetes Care; 2014 Dec; 37(12):3270-8. PubMed ID: 25249651
[TBL] [Abstract][Full Text] [Related]
10. Next-generation GLP-1 therapy: an introduction to liraglutide.
Repas T
Postgrad Med; 2011 Sep; 123(5):239-47. PubMed ID: 21904107
[TBL] [Abstract][Full Text] [Related]
11. Treatment evaluation of liraglutide in type 2 diabetes.
Kela R; Davies MJ
Expert Opin Biol Ther; 2012 Nov; 12(11):1551-6. PubMed ID: 22897447
[TBL] [Abstract][Full Text] [Related]
12. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus.
Vilsbøll T; Brock B; Perrild H; Levin K; Lervang HH; Kølendorf K; Krarup T; Schmitz O; Zdravkovic M; Le-Thi T; Madsbad S
Diabet Med; 2008 Feb; 25(2):152-6. PubMed ID: 18201212
[TBL] [Abstract][Full Text] [Related]
13. Native Oxyntomodulin Has Significant Glucoregulatory Effects Independent of Weight Loss in Obese Humans With and Without Type 2 Diabetes.
Shankar SS; Shankar RR; Mixson LA; Miller DL; Pramanik B; O'Dowd AK; Williams DM; Frederick CB; Beals CR; Stoch SA; Steinberg HO; Kelley DE
Diabetes; 2018 Jun; 67(6):1105-1112. PubMed ID: 29545266
[TBL] [Abstract][Full Text] [Related]
14. [Protective effects of glucagon-like peptide-1 on beta-cells: preclinical and clinical data].
Consoli A; Di Biagio R
G Ital Cardiol (Rome); 2011 Dec; 12(12 Suppl 2):5-9. PubMed ID: 22158421
[TBL] [Abstract][Full Text] [Related]
15. Retrospective analysis of safety and efficacy of liraglutide monotherapy and sulfonylurea-combination therapy in Japanese type 2 diabetes: Association of remaining β-cell function and achievement of HbA1c target one year after initiation.
Usui R; Yabe D; Kuwata H; Murotani K; Kurose T; Seino Y
J Diabetes Complications; 2015; 29(8):1203-10. PubMed ID: 26279320
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of liraglutide as a follow-up therapy after resolution of glucotoxicity with intensive insulin therapy.
Arakawa M; Ebato C
Diabetes Metab Syndr; 2013; 7(4):223-5. PubMed ID: 24290089
[TBL] [Abstract][Full Text] [Related]
17. The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA Trial.
Kramer CK; Zinman B; Choi H; Connelly PW; Retnakaran R
J Clin Endocrinol Metab; 2015 Oct; 100(10):3702-9. PubMed ID: 26230296
[TBL] [Abstract][Full Text] [Related]
18. The effect of liraglutide on endothelial function in patients with type 2 diabetes.
Nandy D; Johnson C; Basu R; Joyner M; Brett J; Svendsen CB; Basu A
Diab Vasc Dis Res; 2014 Nov; 11(6):419-30. PubMed ID: 25212693
[TBL] [Abstract][Full Text] [Related]
19. Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function.
Kielgast U; Krarup T; Holst JJ; Madsbad S
Diabetes Care; 2011 Jul; 34(7):1463-8. PubMed ID: 21593296
[TBL] [Abstract][Full Text] [Related]
20. Liraglutide: can it make a difference in the treatment of type 2 diabetes?
Unger J
Int J Clin Pract Suppl; 2010 Oct; (167):1-3. PubMed ID: 20949698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
